SCHEMBL223853

SCHEMBL223853

Cc1ccc(N2C=CN(c3ccc(C)cc3)C2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
TDP1 Q9NUW8 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
F2 P00734 1/20 0.42
ELANE P08246 1/20 0.42
CTSG P08311 1/20 0.42
CMA1 P23946 1/20 0.42
CTRC Q99895 1/20 0.42
ACHE P22303 1/20 0.42
ADRB1 P08588 1/20 0.41
MGLL Q99685 1/20 0.39
HTT P42858 1/20 0.38
ALOX5 P09917 1/20 0.36
TSHR P16473 2/20 0.36
NOTUM Q6P988 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALOX15 P16050 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL820585 0.97 MAPT (0.41) MAPTTDP1NPSR1LMNAL3MBTL1
SCHEMBL13490255 0.82 NPSR1 (0.40) MAPTTDP1NPSR1LMNAL3MBTL1
Bromide SCHEMBL1884091 0.80 ALDH1A1 (0.34) MAPTTDP1NPSR1LMNAL3MBTL1
Hydrochloric Acid SCHEMBL28977637 0.78 MAPT (0.33) MAPTTDP1NPSR1LMNAL3MBTL1
Bromide SCHEMBL1883012 0.77 DHFR (0.33) MAPTTDP1NPSR1LMNAL3MBTL1
SCHEMBL20414976 0.74 ALDH1A1 (0.41) MAPTTDP1NPSR1LMNAMGLL
SCHEMBL4272763 0.74 LMNA (0.42) MAPTLMNAF2ELANEADRB1
SCHEMBL4760153 0.74 ALDH1A1 (0.40) MAPTNPSR1LMNAL3MBTL1TSHR
SCHEMBL18964692 0.73 ALDH1A1 (0.50) MAPTTDP1NPSR1LMNAL3MBTL1
SCHEMBL9678667 0.72 ADRB1 (0.56) MAPTTDP1NPSR1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112805313-B Low density curable compositions SIKA技术股份公司 2023-02-28 CN disclosed
EP-2826802-B1 METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION ZEON CORP (JP) 2021-03-10 EP disclosed
EP-2574187-B1 SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME AMYRIS INC (US) 2019-09-11 EP disclosed
CN-108864198-A One kind is used as transient metal complex and its application of phosphor material 烟台显华光电材料研究院有限公司 2018-11-23 CN disclosed
CN-108676037-A One kind is used as transient metal complex and its application of phosphor material 烟台显华光电材料研究院有限公司 2018-10-19 CN disclosed
CN-108676038-A One kind is used as transient metal complex and its application of phosphor material 烟台显华光电材料研究院有限公司 2018-10-19 CN disclosed
CN-108440605-A One kind is used as transient metal complex and its application of phosphor material 烟台显华光电材料研究院有限公司 2018-08-24 CN disclosed
US-20180127520-A1 METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION ZEON CORPORATION (JP) 2018-05-10 US disclosed
US-9850325-B2 Method for producing ring-opening metathesis polymer hydride, and resin composition ZEON CORPORATION (JP) 2017-12-26 US disclosed
EP-2116302-B1 Catalyst complex with a heterocyclic carbene ligand UNIV OF NEW ORLEANS FOUND (US) 2017-02-22 EP disclosed
US-20040210055-A1 stable to air, moisture, and thermal degradation; for olefin metathesis NOLAN STEVEN P 2004-10-21 US disclosed
US-6613851-B1 Cyclic carbene- eta -ligand complexes for catalysis of olefin polymerization. BOREALIS TECHNOLOGY OY (FI) 2003-09-02 US disclosed
US-20030050406-A1 Process for producing hydrogenated product of cyclic olefin polymer prepared through ring-opening polymerization ZEON CORPORATION 2003-03-13 US disclosed
US-20030018138-A1 Copolymer formed by ring -opening polymerization, product of hydrogenation of copolymer formed by ring-opening polymerization, and process for producing these ZEON CORPORATION (JP) 2003-01-23 US disclosed
EP-1275675-A1 COPOLYMER FORMED BY RING-OPENING POLYMERIZATION, PRODUCT OF HYDROGENATION OF COPOLYMER FORMED BY RING-OPENING POLYMERIZATION, AND PROCESSES FOR PRODUCING THESE Zeon Corporation (JP) 2003-01-15 EP disclosed
US-6486264-B1 Process for producing hydrogenated ring-opening polymerization polymer of cycloolefin ZEON CORPORATION (JP) 2002-11-26 US disclosed
EP-1115491-A4 CATALYST COMPLEX WITH CARBENE LIGAND UNIV NEW ORLEANS FOUNDATION (US) 2002-11-20 EP disclosed
EP-1197509-A1 PROCESS FOR PRODUCING HYDROGENATED RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN Nippon Zeon Co., Ltd. (JP) 2002-04-17 EP disclosed
EP-1115491-A1 CATALYST COMPLEX WITH CARBENE LIGAND University Of New Orleans Foundation (US) 2001-07-18 EP disclosed
WO-2000015339-A1 CATALYST COMPLEX WITH CARBENE LIGAND UNIVERSITY OF NEW ORLEANS FOUNDATION (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040210055-A1 stable to air, moisture, and thermal degradation; for olefin metathesis MDM2, MYC, MYCBP MAPT 2028/4885TDP1 4125/4885NPSR1 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.